MedTrace Logo

Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies

NCT03366350 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-05-10

No results posted yet for this study

Summary

This is the second stage of the previous anti-CD19 CAR-T therapy (NCT02965092). The study aims to evaluate the safety and efficacy of consolidative allo-HSCT following CAR-T therapy in patients with relapsed or refractory B cell Malignancies.

Conditions

Interventions

PROCEDURE

Allogeneic hematological stem cell transplantation

Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Jingzhou Central Hospital

    collaborator OTHER

  • Xiangyang Central Hospital

    collaborator OTHER

  • People Hospital Of Yichang

    collaborator UNKNOWN

  • Wuhan Sian Medical Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • YU HU, M.D., Ph.D · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-15
Primary Completion
2021-01-01
Completion
2021-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03366350 on ClinicalTrials.gov